Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
The iShares U.S. Pharmaceuticals ETF (IHE) provides exposure to U.S. companies in the pharmaceuticals sector, focusing on firms engaged in the research, development, manufacturing, and marketing of pharmaceuticals. The ETF's competitive position is bolstered by its diversified holdings across major pharmaceutical players, including large-cap firms like Pfizer and Johnson & Johnson, which are well-established in both domestic and international markets.
IHE generates revenue primarily through management fees based on the total assets under management. The ETF benefits from economies of scale as it grows, allowing it to maintain competitive fee structures while providing investors with diversified exposure to the pharmaceuticals sector.
Changes in pharmaceutical sector performance driven by drug approvals and patent expirations
Market sentiment regarding healthcare reforms and drug pricing regulations
Mergers and acquisitions within the pharmaceutical industry
Overall performance of the broader equity markets impacting investor sentiment towards ETFs
Regulatory changes affecting drug pricing and approval processes
Technological disruption in drug development and delivery
Emergence of generic drugs impacting revenue of branded pharmaceuticals
Increased competition from biotech firms and alternative therapies
Market volatility impacting AUM and management fees
Potential liquidity risks if significant redemptions occur
moderate - The pharmaceuticals sector is somewhat insulated from economic downturns, but overall consumer spending and healthcare budgets can impact growth.
Rising interest rates can lead to higher borrowing costs for pharmaceutical companies, potentially impacting their profitability and, in turn, the ETF's performance.
minimal - The ETF is not directly dependent on credit conditions, but broader market sentiment can influence investor behavior.
growth - Investors looking for exposure to the pharmaceutical sector's growth potential, particularly in biotech innovations.
moderate - The ETF's beta is typically lower than that of the broader market, reflecting its diversified nature.
